{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:29:10Z","timestamp":1793968150359,"version":"4.8.0"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00849-2","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:27:07Z","timestamp":1792668427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design"],"prefix":"10.1186","volume":"15","author":[{"given":"Amir Abbas","family":"Hamidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-0457","authenticated-orcid":false,"given":"Omeed","family":"Moaven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reihaneh Alsadat","family":"Mahmoudian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4539-048X","authenticated-orcid":false,"given":"Mohammad Reza","family":"Abbaszadegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"1","key":"849_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu DK, Nissley DV, McCormick F. RAS Proteins and Their Regulators in Human Disease. Cell. 2017;170(1):17\u201333.","journal-title":"Cell"},{"issue":"15","key":"849_CR2","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/j.molcel.2024.06.027","volume":"84","author":"AM Mozzarelli","year":"2024","unstructured":"Mozzarelli AM, Simanshu DK, Castel P. Functional and structural insights into RAS effector proteins. Mol Cell. 2024;84(15):2807\u201321.","journal-title":"Mol Cell"},{"issue":"3","key":"849_CR3","doi-asserted-by":"publisher","first-page":"a031500","DOI":"10.1101\/cshperspect.a031500","volume":"9","author":"K Scheffzek","year":"2019","unstructured":"Scheffzek K, Shivalingaiah G. Ras-specific GTPase-activating proteins: structures, mechanisms, and interactions. Cold Spring Harb Perspect Med. 2019;9(3):a031500. https:\/\/doi.org\/10.1101\/cshperspect.a031500.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"21","key":"849_CR4","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.1158\/0008-5472.CAN-22-1731","volume":"82","author":"RB Scharpf","year":"2022","unstructured":"Scharpf RB, Balan A, Ricciuti B, Fiksel J, Cherry C, Wang C, et al. Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers. Cancer Res. 2022;82(21):4058\u201378.","journal-title":"Cancer Res"},{"issue":"14","key":"849_CR5","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The Frequency of Ras Mutations in Cancer. Cancer Res. 2020;80(14):2969\u201374.","journal-title":"Cancer Res"},{"issue":"2","key":"849_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"BJ Raphael","year":"2017","unstructured":"Raphael BJ, Hruban RH, Aguirre AJ, Moffitt RA, Yeh JJ, Stewart C, et al. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32(2):185\u2013e20313.","journal-title":"Cancer Cell"},{"issue":"7407","key":"849_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"DM Muzny","year":"2012","unstructured":"Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330\u20137.","journal-title":"Nature"},{"issue":"7511","key":"849_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"EA Collisson","year":"2014","unstructured":"Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543\u201350.","journal-title":"Nature"},{"issue":"6","key":"849_CR9","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-24-3149","volume":"31","author":"B Ardalan","year":"2025","unstructured":"Ardalan B, Ciner A, Baca Y, Hinton A, Darabi S, Kasi A, et al. Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma. Clin Cancer Res. 2025;31(6):1082\u201390.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"849_CR10","doi-asserted-by":"publisher","first-page":"e981","DOI":"10.1093\/oncolo\/oyad138","volume":"28","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Yoshino T, Stevinson K, Eichinger CS, Giannopoulou C, Rehn M, et al. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review. Oncologist. 2023;28(11):e981\u201394.","journal-title":"Oncologist"},{"issue":"7","key":"849_CR11","first-page":"1681","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani R, Akdemir Kadir C, Aksoy BA, Albert M, Ally A, Amin Samirkumar B, et al. Genomic Classif Cutan Melanoma Cell. 2015;161(7):1681\u201396.","journal-title":"Genomic Classif Cutan Melanoma Cell"},{"issue":"11","key":"849_CR12","doi-asserted-by":"publisher","first-page":"e13821","DOI":"10.1371\/journal.pone.0013821","volume":"5","author":"LC Kompier","year":"2010","unstructured":"Kompier LC, van der Lurkin I, van Rhijn BWG, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy. PLoS ONE. 2010;5(11):e13821.","journal-title":"PLoS ONE"},{"issue":"14","key":"849_CR13","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1200\/JCO.23.00205","volume":"41","author":"MS Phadke","year":"2023","unstructured":"Phadke MS, Smalley KSM. Targeting NRAS Mutations in Advanced Melanoma. J Clin Oncol. 2023;41(14):2661\u20134.","journal-title":"J Clin Oncol"},{"key":"849_CR14","doi-asserted-by":"publisher","first-page":"e2200211","DOI":"10.1200\/PO.22.00211","volume":"7","author":"N Coleman","year":"2023","unstructured":"Coleman N, Marcelo KL, Hopkins JF, Khan NI, Du R, Hong L, et al. HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma. JCO Precis Oncol. 2023;7:e2200211.","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"849_CR15","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1210\/jc.2002-021186","volume":"88","author":"V Vasko","year":"2003","unstructured":"Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab. 2003;88(6):2745\u201352. https:\/\/doi.org\/10.1210\/jc.2002-021186.","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"849_CR16","doi-asserted-by":"publisher","first-page":"10908","DOI":"10.3390\/ijms262210908","volume":"26","author":"D Cho","year":"2025","unstructured":"Cho D, Shin K, Hong TH, Lee SH, Kim Y, Kim IH, et al. Clinical and molecular characteristics of KRAS codon-specific mutations in advanced pancreatic ductal adenocarcinoma with prognostic and therapeutic implications. Int J Mol Sci. 2025;26(22):10908.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"849_CR17","first-page":"67","volume":"22","author":"J Malhotra","year":"2024","unstructured":"Malhotra J, Nguyen D, Tan T, Semeniuk GB III. Management of KRAS-mutated non-small cell lung cancer. Clin Adv Hematol Oncol. 2024;22(2):67\u201375.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"849_CR18","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.21037\/tlcr-20-455","volume":"9","author":"HH Loong","year":"2020","unstructured":"Loong HH, Du N, Cheng C, Lin H, Guo J, Lin G, et al. KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. Transl Lung Cancer Res. 2020;9(5):1759\u201369.","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"849_CR19","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission Possible? Nat Rev Drug Discovery. 2014;13(11):828\u201351.","journal-title":"Nat Rev Drug Discovery"},{"issue":"13","key":"849_CR20","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1917239.","journal-title":"N Engl J Med"},{"issue":"3","key":"849_CR21","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","volume":"172","author":"MR Janes","year":"2018","unstructured":"Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018;172(3):578\u2013e8917.","journal-title":"Cell"},{"issue":"1","key":"849_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ccell.2019.12.009","volume":"37","author":"F McCormick","year":"2020","unstructured":"McCormick F. Sticking it to KRAS: Covalent Inhibitors Enter the Clinic. Cancer Cell. 2020;37(1):3\u20134.","journal-title":"Cancer Cell"},{"key":"849_CR23","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to adagrasib for KRAS G12C-mutated non-small-cell lung cancer. 12. Dec 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc. Accessed 22 Jul 2026."},{"key":"849_CR24","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to sotorasib for KRAS G12C-mutated non-small-cell lung cancer. 28. May 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc. Accessed 22 Jul 2026."},{"issue":"25","key":"849_CR25","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021;384(25):2371\u201381.","journal-title":"N Engl J Med"},{"issue":"1","key":"849_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","volume":"30","author":"Y Kuboki","year":"2024","unstructured":"Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, et al. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024;30(1):265\u201370.","journal-title":"Nat Med"},{"issue":"8","key":"849_CR27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, et al. EGFR Blockade Reverts Resistance to KRAS(G12C) Inhibition in Colorectal Cancer. Cancer Discov. 2020;10(8):1129\u201339.","journal-title":"Cancer Discov"},{"issue":"1","key":"849_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;388(1):44\u201354.","journal-title":"N Engl J Med"},{"issue":"23","key":"849_CR29","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;389(23):2125\u201339.","journal-title":"N Engl J Med"},{"issue":"1","key":"849_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","volume":"23","author":"MG Fakih","year":"2022","unstructured":"Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, et al. Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2022;23(1):115\u201324.","journal-title":"Lancet Oncol"},{"issue":"18","key":"849_CR31","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","volume":"394","author":"BM Wolpin","year":"2026","unstructured":"Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, et al. Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer. N Engl J Med. 2026;394(18):1790\u2013802. https:\/\/doi.org\/10.1056\/NEJMoa2505783.","journal-title":"N Engl J Med"},{"issue":"4","key":"849_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2605555","volume":"395","author":"EM O\u2019Reilly","year":"2026","unstructured":"O\u2019Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. 2026;395(4):325\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2605555.","journal-title":"N Engl J Med"},{"issue":"14","key":"849_CR33","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMoa2600752","volume":"394","author":"W Park","year":"2026","unstructured":"Park W, Kasi A, Spira AI, Paz-Ares Rodriguez L, Herzberg BO, Pelster MS, et al. Setidegrasib in advanced non-small-cell lung cancer and pancreatic cancer. N Engl J Med. 2026;394(14):1409\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2600752.","journal-title":"N Engl J Med"},{"key":"849_CR34","unstructured":"US Food and Drug Administration. FDA permits expanded access for investigational pancreatic cancer drug. Published May 1, 2026. Accessed July 22. 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-permits-expanded-access-investigational-pancreatic-cancer-drug"},{"key":"849_CR35","unstructured":"US Food and Drug Administration. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. 26. Aug 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma. Accessed 29 Aug 2026."},{"issue":"7886","key":"849_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Murciano-Goroff YR, Xue JY, Ang A, Lucas J, Mai TT, et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature. 2021;599(7886):679\u201383.","journal-title":"Nature"},{"issue":"1","key":"849_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","volume":"13","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Mezzadra R, Sinopoli J, Bian Y, Marasco M, Kaplun E, et al. Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer. Cancer Discov. 2023;13(1):41\u201355.","journal-title":"Cancer Discov"},{"issue":"25","key":"849_CR38","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired Resistance to KRAS(G12C) Inhibition in Cancer. N Engl J Med. 2021;384(25):2382\u201393.","journal-title":"N Engl J Med"},{"issue":"8","key":"849_CR39","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"N Tanaka","year":"2021","unstructured":"Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, et al. Clinical Acquired Resistance to KRAS(G12C) Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Cancer Discov. 2021;11(8):1913\u201322.","journal-title":"Cancer Discov"},{"issue":"7","key":"849_CR40","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/2159-8290.CD-25-0349","volume":"15","author":"RY Ebright","year":"2025","unstructured":"Ebright RY, Dilly J, Shaw AT, Aguirre AJ. Response and Resistance to RAS Inhibition in Cancer. Cancer Discov. 2025;15(7):1325\u201349.","journal-title":"Cancer Discov"},{"issue":"10","key":"849_CR41","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41571-025-01058-2","volume":"22","author":"EW Thompson","year":"2025","unstructured":"Thompson EW, Redfern AD, Brabletz S, Berx G, Agarwal V, Ganesh K, et al. EMT and cancer: what clinicians should know. Nat Reviews Clin Oncol. 2025;22(10):711\u201333.","journal-title":"Nat Reviews Clin Oncol"},{"key":"849_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12943-025-02364-0","volume":"24","author":"X Wang","year":"2025","unstructured":"Wang X, Wu J, Xiao A, Wang J, et al. Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs. Mol Cancer. 2025;24:229.","journal-title":"Mol Cancer"},{"key":"849_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12943-024-02216-3","volume":"24","author":"Y Shi","year":"2025","unstructured":"Shi Y, Zheng H, Wang T, Zhou S, Zhao S, Li M, et al. Targeting KRAS: from metabolic regulation to cancer treatment. Mol Cancer. 2025;24:9.","journal-title":"Mol Cancer"},{"key":"849_CR44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12943-025-02338-2","volume":"24","author":"H Allgayer","year":"2025","unstructured":"Allgayer H, Mahapatra S, Mishra B, Swain B, Saha S, Khanra S, et al. Epithelial-to-mesenchymal transition and cancer metastasis: the status quo of methods and experimental models 2025. Mol Cancer. 2025;24:167.","journal-title":"Mol Cancer"},{"key":"849_CR45","doi-asserted-by":"publisher","first-page":"659861","DOI":"10.3389\/fmolb.2021.659861","volume":"8","author":"C Busquets-Hern\u00e1ndez","year":"2021","unstructured":"Busquets-Hern\u00e1ndez C, Triola G. Palmitoylation as a key regulator of Ras localization and function. Front Mol Biosci. 2021;8:659861. https:\/\/doi.org\/10.3389\/fmolb.2021.659861.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"849_CR46","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1042\/BST20221347","volume":"51","author":"J Kochen Rossi","year":"2023","unstructured":"Kochen Rossi J, Nuevo-Tapioles C, Philips MR. Differential functions of the KRAS splice variants. Biochem Soc Trans. 2023;51(3):1191\u20139.","journal-title":"Biochem Soc Trans"},{"issue":"3","key":"849_CR47","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1158\/0008-5472.CAN-17-2727","volume":"78","author":"R Nussinov","year":"2018","unstructured":"Nussinov R, Tsai CJ, Jang H. Oncogenic Ras Isoforms Signaling Specificity at the Membrane. Cancer Res. 2018;78(3):593\u2013602.","journal-title":"Cancer Res"},{"issue":"2","key":"849_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.semcdb.2011.09.002","volume":"23","author":"IA Prior","year":"2012","unstructured":"Prior IA, Hancock JF. Ras trafficking, localization and compartmentalized signalling. Semin Cell Dev Biol. 2012;23(2):145\u201353.","journal-title":"Semin Cell Dev Biol"},{"issue":"44","key":"849_CR49","doi-asserted-by":"publisher","first-page":"E6766","DOI":"10.1073\/pnas.1615316113","volume":"113","author":"S Dharmaiah","year":"2016","unstructured":"Dharmaiah S, Bindu L, Tran TH, Gillette WK, Frank PH, Ghirlando R, et al. Structural basis of recognition of farnesylated and methylated KRAS4b by PDE\u03b4. Proc Natl Acad Sci U S A. 2016;113(44):E6766\u201375.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"849_CR50","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1242\/jcs.182873","volume":"129","author":"GA Hobbs","year":"2016","unstructured":"Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129(7):1287\u201392.","journal-title":"J Cell Sci"},{"issue":"2","key":"849_CR51","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.bbrc.2017.04.063","volume":"487","author":"MC Gregory","year":"2017","unstructured":"Gregory MC, McLean MA, Sligar SG. Interaction of KRas4b with anionic membranes: A special role for PIP2. Biochem Biophys Res Commun. 2017;487(2):351\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"849_CR52","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00232-021-00176-z","volume":"254","author":"CA L\u00f3pez","year":"2021","unstructured":"L\u00f3pez CA, Agarwal A, Van QN, Stephen AG, Gnanakaran S. Unveiling the Dynamics of KRAS4b on Lipid Model Membranes. J Membr Biol. 2021;254(2):201\u201316.","journal-title":"J Membr Biol"},{"issue":"18","key":"849_CR53","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1016\/j.bpj.2021.08.008","volume":"120","author":"F Heinrich","year":"2021","unstructured":"Heinrich F, Van QN, Jean-Francois F, Stephen AG, L\u00f6sche M. Membrane-bound KRAS approximates an entropic ensemble of configurations. Biophys J. 2021;120(18):4055\u201366.","journal-title":"Biophys J"},{"issue":"3","key":"849_CR54","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3390\/biom11030377","volume":"11","author":"QN Van","year":"2021","unstructured":"Van QN, Prakash P, Shrestha R, Balius TE, Turbyville TJ, Stephen AG. RAS Nanoclusters: Dynamic Signaling Platforms Amenable to Therapeutic Intervention. Biomolecules. 2021;11(3):377.","journal-title":"Biomolecules"},{"issue":"11","key":"849_CR55","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.tibs.2024.09.005","volume":"49","author":"AG Stephen","year":"2024","unstructured":"Stephen AG. Two hearts beat as one: the debate over RAS dimers continues. Trends Biochem Sci. 2024;49(11):933\u20135.","journal-title":"Trends Biochem Sci"},{"issue":"7","key":"849_CR56","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","volume":"29","author":"J Liu","year":"2022","unstructured":"Liu J, Kang R, Tang D. The KRAS-G12C inhibitor: activity and resistance. Cancer Gene Ther. 2022;29(7):875\u20138.","journal-title":"Cancer Gene Ther"},{"key":"849_CR57","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3389\/fonc.2019.01088","volume":"9","author":"C Mu\u00f1oz-Maldonado","year":"2019","unstructured":"Mu\u00f1oz-Maldonado C, Zimmer Y, Medov\u00e1 M. A comparative analysis of individual RAS mutations in cancer biology. Front Oncol. 2019;9:1088. https:\/\/doi.org\/10.3389\/fonc.2019.01088.","journal-title":"Front Oncol"},{"key":"849_CR58","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.csbj.2020.04.003","volume":"18","author":"S Vatansever","year":"2020","unstructured":"Vatansever S, Erman B, G\u00fcm\u00fc\u015f ZH. Comparative effects of oncogenic mutations G12C, G12V, G13D, and Q61H on local conformations and dynamics of K-Ras. Comput Struct Biotechnol J. 2020;18:1000\u201311.","journal-title":"Comput Struct Biotechnol J"},{"key":"849_CR59","doi-asserted-by":"publisher","first-page":"21949","DOI":"10.1038\/srep21949","volume":"6","author":"S Lu","year":"2016","unstructured":"Lu S, Jang H, Nussinov R, Zhang J. The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B. Sci Rep. 2016;6:21949.","journal-title":"Sci Rep"},{"issue":"6","key":"849_CR60","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang J, Jiang L, Maldonato BJ, Wang Y, Holderfield M, Aronchik I, et al. Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers. Cancer Discov. 2024;14(6):994\u20131017.","journal-title":"Cancer Discov"},{"issue":"8","key":"849_CR61","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2303810","volume":"389","author":"A Sacher","year":"2023","unstructured":"Sacher A, LoRusso P, Patel MR, Miller WH Jr., Garralda E, Forster MD, et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med. 2023;389(8):710\u201321.","journal-title":"N Engl J Med"},{"key":"849_CR62","doi-asserted-by":"publisher","first-page":"102238","DOI":"10.1016\/j.ctrv.2021.102238","volume":"99","author":"T Randic","year":"2021","unstructured":"Randic T, Kozar I, Margue C, Utikal J, Kreis S. NRAS mutant melanoma: Towards better therapies. Cancer Treat Rev. 2021;99:102238.","journal-title":"Cancer Treat Rev"},{"issue":"7287","key":"849_CR63","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","volume":"464","author":"PI Poulikakos","year":"2010","unstructured":"Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427\u201330.","journal-title":"Nature"},{"issue":"7287","key":"849_CR64","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature08833","volume":"464","author":"G Hatzivassiliou","year":"2010","unstructured":"Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431\u20135.","journal-title":"Nature"},{"issue":"4","key":"849_CR65","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","volume":"18","author":"R Dummer","year":"2017","unstructured":"Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(4):435\u201345.","journal-title":"Lancet Oncol"},{"issue":"1","key":"849_CR66","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41698-025-01166-3","volume":"9","author":"M Navarro-Jim\u00e9nez","year":"2025","unstructured":"Navarro-Jim\u00e9nez M, Gonz\u00e1lez B, Mulet N, Hierro C, Alonso S. KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials. NPJ Precis Oncol. 2025;9(1):380.","journal-title":"NPJ Precis Oncol"},{"issue":"9","key":"849_CR67","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/1758834017719829","volume":"9","author":"P Garrido","year":"2017","unstructured":"Garrido P, Olmedo ME, G\u00f3mez A, Paz Ares L, L\u00f3pez-R\u00edos F, Rosa-Rosa JM, et al. Treating KRAS-mutant NSCLC: latest evidence and clinical consequences. Ther Adv Med Oncol. 2017;9(9):589\u201397.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"849_CR68","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41698-021-00237-5","volume":"5","author":"G Palma","year":"2021","unstructured":"Palma G, Khurshid F, Lu K, Woodward B, Husain H. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes. NPJ Precis Oncol. 2021;5(1):98.","journal-title":"NPJ Precis Oncol"},{"issue":"7536","key":"849_CR69","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"MS Lawrence","year":"2015","unstructured":"Lawrence MS, Sougnez C, Lichtenstein L, Cibulskis K, Lander E, Gabriel SB, et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576\u201382.","journal-title":"Nature"},{"issue":"7","key":"849_CR70","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.3390\/ijms26073093","volume":"26","author":"H Ohshima","year":"2025","unstructured":"Ohshima H, Kobayashi E, Inaba M, Nakazawa R, Hirai N, Ueno T, et al. HRAS mutations in head and neck carcinomas in Japanese patients: clinical significance, prognosis, and therapeutic potential. Int J Mol Sci. 2025;26(7):3093. https:\/\/doi.org\/10.3390\/ijms26073093.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"849_CR71","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676\u201390.","journal-title":"Cell"},{"key":"849_CR72","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semcancer.2019.06.007","volume":"59","author":"AK Murugan","year":"2019","unstructured":"Murugan AK, Grieco M, Tsuchida N. RAS mutations in human cancers: Roles in precision medicine. Sem Cancer Biol. 2019;59:23\u201335.","journal-title":"Sem Cancer Biol"},{"issue":"1","key":"849_CR73","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-024-01054-2","volume":"14","author":"D Alawieh","year":"2024","unstructured":"Alawieh D, Cysique-Foinlan L, Willekens C, Renneville A. RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives. Blood Cancer J. 2024;14(1):72.","journal-title":"Blood Cancer J"},{"issue":"5","key":"849_CR74","doi-asserted-by":"publisher","first-page":"716","DOI":"10.7150\/jca.17779","volume":"8","author":"A Tyutyunnykova","year":"2017","unstructured":"Tyutyunnykova A, Telegeev G, Dubrovska A. The controversial role of phospholipase C epsilon (PLC\u03b5) in cancer development and progression. J Cancer. 2017;8(5):716\u201329.","journal-title":"J Cancer"},{"issue":"12","key":"849_CR75","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1016\/j.bbamcr.2014.09.004","volume":"1843","author":"LR Gentry","year":"2014","unstructured":"Gentry LR, Martin TD, Reiner DJ, Der CJ. Ral small GTPase signaling and oncogenesis: More than just 15 minutes of fame. Biochim Biophys Acta. 2014;1843(12):2976\u201388.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"849_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.117.014415","volume":"70","author":"C Yan","year":"2018","unstructured":"Yan C, Theodorescu D. RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer. Pharmacol Rev. 2018;70(1):1\u201311.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"849_CR77","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ng.3218","volume":"47","author":"L Lin","year":"2015","unstructured":"Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015;47(3):250\u20136.","journal-title":"Nat Genet"},{"issue":"2","key":"849_CR78","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/biom11020236","volume":"11","author":"C Kiel","year":"2021","unstructured":"Kiel C, Matallanas D, Kolch W. The ins and outs of RAS effector complexes. Biomolecules. 2021;11(2):236.","journal-title":"Biomolecules"},{"issue":"10","key":"849_CR79","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med. 2022;28(10):2171\u201382.","journal-title":"Nat Med"},{"issue":"7","key":"849_CR80","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/genes12071094","volume":"12","author":"C Cuesta","year":"2021","unstructured":"Cuesta C, Ar\u00e9valo-Alameda C, Castellano E. The Importance of Being PI3K in the RAS Signaling Network. Genes. 2021;12(7):1094.","journal-title":"Genes"},{"issue":"1","key":"849_CR81","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Therapy. 2021;6(1):425.","journal-title":"Signal Transduct Target Therapy"},{"issue":"6","key":"849_CR82","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","volume":"36","author":"MC Mendoza","year":"2011","unstructured":"Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320\u20138.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"849_CR83","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41698-018-0049-y","volume":"2","author":"WJ Jeong","year":"2018","unstructured":"Jeong WJ, Ro EJ, Choi KY. Interaction between Wnt\/\u03b2-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of \u03b2-catenin and RAS by targeting the Wnt\/\u03b2-catenin pathway. NPJ Precis Oncol. 2018;2(1):5.","journal-title":"NPJ Precis Oncol"},{"issue":"7","key":"849_CR84","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41580-018-0007-0","volume":"19","author":"CJ David","year":"2018","unstructured":"David CJ, Massagu\u00e9 J. Contextual determinants of TGF\u03b2 action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018;19(7):419\u201335.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7791","key":"849_CR85","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-019-1897-5","volume":"577","author":"J Su","year":"2020","unstructured":"Su J, Morgani SM, David CJ, Wang Q, Er EE, Huang Y-H, et al. TGF-\u03b2 orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1. Nature. 2020;577(7791):566\u201371.","journal-title":"Nature"},{"issue":"16","key":"849_CR86","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1016\/j.febslet.2014.04.012","volume":"588","author":"BC Low","year":"2014","unstructured":"Low BC, Pan CQ, Shivashankar GV, Bershadsky A, Sudol M, Sheetz M. YAP\/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. FEBS Lett. 2014;588(16):2663\u201370.","journal-title":"FEBS Lett"},{"issue":"1","key":"849_CR87","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ccr.2011.12.006","volume":"21","author":"J Ling","year":"2012","unstructured":"Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, et al. KrasG12D-induced IKK2\/\u03b2\/NF-\u03baB activation by IL-1\u03b1 and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(1):105\u201320.","journal-title":"Cancer Cell"},{"issue":"1","key":"849_CR88","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cell.2014.06.003","volume":"158","author":"A Kapoor","year":"2014","unstructured":"Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, et al. Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. Cell. 2014;158(1):185\u201397.","journal-title":"Cell"},{"issue":"4","key":"849_CR89","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1053\/j.gastro.2006.08.011","volume":"131","author":"KP Janssen","year":"2006","unstructured":"Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, et al. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology. 2006;131(4):1096\u2013109.","journal-title":"Gastroenterology"},{"issue":"22","key":"849_CR90","doi-asserted-by":"publisher","first-page":"6182","DOI":"10.1016\/j.cell.2024.08.014","volume":"187","author":"JH Lee","year":"2024","unstructured":"Lee JH, S\u00e1nchez-Rivera FJ, He L, Basnet H, Chen FX, Spina E, et al. TGF-\u03b2 and RAS jointly unmask primed enhancers to drive metastasis. Cell. 2024;187(22):6182\u2013e9929.","journal-title":"Cell"},{"issue":"5","key":"849_CR91","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.cell.2016.01.009","volume":"164","author":"CJ David","year":"2016","unstructured":"David CJ, Huang YH, Chen M, Su J, Zou Y, Bardeesy N, et al. TGF-\u03b2 Tumor Suppression through a Lethal EMT. Cell. 2016;164(5):1015\u201330.","journal-title":"Cell"},{"issue":"23","key":"849_CR92","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1007\/s00018-016-2297-8","volume":"73","author":"D Lake","year":"2016","unstructured":"Lake D, Corr\u00eaa SAL, M\u00fcller J. Negative feedback regulation of the ERK1\/2 MAPK pathway. Cell Mol Life Sci. 2016;73(23):4397\u2013413.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"849_CR93","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","volume":"9","author":"R Yaeger","year":"2019","unstructured":"Yaeger R, Corcoran RB. Targeting Alterations in the RAF-MEK Pathway. Cancer Discov. 2019;9(3):329\u201341.","journal-title":"Cancer Discov"},{"issue":"10","key":"849_CR94","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","volume":"8","author":"C Fedele","year":"2018","unstructured":"Fedele C, Ran H, Diskin B, Wei W, Jen J, Geer MJ, et al. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. Cancer Discov. 2018;8(10):1237\u201349.","journal-title":"Cancer Discov"},{"issue":"8","key":"849_CR95","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/ni.2060","volume":"12","author":"Y Ben-Neriah","year":"2011","unstructured":"Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-\u03baB as the matchmaker. Nat Immunol. 2011;12(8):715\u201323.","journal-title":"Nat Immunol"},{"issue":"600","key":"849_CR96","doi-asserted-by":"publisher","first-page":"eaaw8288","DOI":"10.1126\/scisignal.aaw8288","volume":"12","author":"T McFall","year":"2019","unstructured":"McFall T, Diedrich JK, Mengistu M, Littlechild SL, Paskvan KV, Sisk-Hackworth L, et al. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy. Sci Signal. 2019;12(600):eaaw8288. https:\/\/doi.org\/10.1126\/scisignal.aaw8288.","journal-title":"Sci Signal"},{"issue":"11","key":"849_CR97","doi-asserted-by":"publisher","first-page":"110096","DOI":"10.1016\/j.celrep.2021.110096","volume":"37","author":"T McFall","year":"2021","unstructured":"McFall T, Stites EC. Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. Cell Rep. 2021;37(11):110096. https:\/\/doi.org\/10.1016\/j.celrep.2021.110096.","journal-title":"Cell Rep"},{"issue":"12","key":"849_CR98","doi-asserted-by":"publisher","first-page":"110993","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan MB, Coker O, Sorokin A, Fella K, Barnes H, Wong E, et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 2022;39(12):110993. https:\/\/doi.org\/10.1016\/j.celrep.2022.110993.","journal-title":"Cell Rep"},{"issue":"1","key":"849_CR99","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41698-022-00329-w","volume":"6","author":"T McFall","year":"2022","unstructured":"McFall T, Trogdon M, Guizar AC, Langenheim JF, Sisk-Hackworth L, Stites EC. Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP. NPJ Precis Oncol. 2022;6(1):86. https:\/\/doi.org\/10.1038\/s41698-022-00329-w.","journal-title":"NPJ Precis Oncol"},{"issue":"624","key":"849_CR100","doi-asserted-by":"publisher","first-page":"eaay6013","DOI":"10.1126\/scisignal.aay6013","volume":"13","author":"CA Stalnecker","year":"2020","unstructured":"Stalnecker CA, Der CJ. RAS, wanted dead or alive: Advances in targeting RAS mutant cancers. Sci Signal. 2020;13(624):eaay6013. https:\/\/doi.org\/10.1126\/scisignal.aay6013.","journal-title":"Sci Signal"},{"issue":"8","key":"849_CR101","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1158\/0008-5472.CAN-25-0018","volume":"86","author":"M Kamgar","year":"2026","unstructured":"Kamgar M, Hobbs GA, Davidson R, Dorbin D, Herrera J, Langenheim JF, et al. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. Cancer Res. 2026;86(8):2042\u201359. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-0018.","journal-title":"Cancer Res"},{"issue":"8","key":"849_CR102","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1158\/0008-5472.CAN-25-2630","volume":"86","author":"RA Burge","year":"2026","unstructured":"Burge RA, Le Roux O, Popow O, Spadafora VK, Rajesh C, Adair SJ, et al. KRASG12R-Mutant Pancreatic Cancer Features Limited ERK\/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Cancer Res. 2026;86(8):1868\u201382. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-2630.","journal-title":"Cancer Res"},{"key":"849_CR103","doi-asserted-by":"crossref","unstructured":"Scaparone P, Mira A, Cheong TC, Patrucco E, Ricciuti B, Gribaudo R, et al. EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway. Cancer Discov. 2026 Jun;22.","DOI":"10.1158\/2159-8290.c.8811895"},{"key":"849_CR104","doi-asserted-by":"publisher","unstructured":"Dorbin D, Herrera J, Davidson R, Chandrashekar NK, Scheuber G, Jayakrishnan P et al. Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. Cancer Res 2026 Aug 27. https:\/\/doi.org\/10.1158\/0008-5472.CAN-26-1181. Online ahead of print.","DOI":"10.1158\/0008-5472.CAN-26-1181"},{"issue":"10","key":"849_CR105","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/0008-5472.CAN-08-4765","volume":"69","author":"S Wee","year":"2009","unstructured":"Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao Y-M, et al. PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers. Cancer Res. 2009;69(10):4286\u201393.","journal-title":"Cancer Res"},{"issue":"13","key":"849_CR106","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","volume":"72","author":"AB Turke","year":"2012","unstructured":"Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA. MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012;72(13):3228\u201337. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3747.","journal-title":"Cancer Res"},{"issue":"1","key":"849_CR107","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","volume":"19","author":"S Chandarlapaty","year":"2011","unstructured":"Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011;19(1):58\u201371. https:\/\/doi.org\/10.1016\/j.ccr.2010.10.031.","journal-title":"Cancer Cell"},{"issue":"3","key":"849_CR108","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/2159-8290.CD-13-0611","volume":"4","author":"M Will","year":"2014","unstructured":"Will M, Qin ACR, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, et al. Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov. 2014;4(3):334\u201347. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0611.","journal-title":"Cancer Discov"},{"issue":"5","key":"849_CR109","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","volume":"25","author":"P Lito","year":"2014","unstructured":"Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 2014;25(5):697\u2013710.","journal-title":"Cancer Cell"},{"issue":"7387","key":"849_CR110","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100\u20133.","journal-title":"Nature"},{"issue":"10","key":"849_CR111","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/2767-9764.CRC-25-0281","volume":"5","author":"RA Burge","year":"2025","unstructured":"Burge RA, Bialousow L, McFall T, Bamonte L, Johnson G, Smith M, et al. Pancreatic Cells Are Resistant to KRASQ61L Expression due to Hyperactive ERK\/MAPK Signaling and Apoptosis Induction. Cancer Res Commun. 2025;5(10):1865\u201378. https:\/\/doi.org\/10.1158\/2767-9764.CRC-25-0281.","journal-title":"Cancer Res Commun"},{"issue":"8044","key":"849_CR112","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41586-024-08283-2","volume":"637","author":"A Cuevas-Navarro","year":"2025","unstructured":"Cuevas-Navarro A, Pourfarjam Y, Hu F, Rodriguez DJ, Vides A, Sang B, et al. Pharmacological restoration of GTP hydrolysis by mutant RAS. Nature. 2025;637(8044):224\u20139. https:\/\/doi.org\/10.1038\/s41586-024-08283-2.","journal-title":"Nature"},{"issue":"5","key":"849_CR113","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7(5):469\u201383.","journal-title":"Cancer Cell"},{"issue":"14","key":"849_CR114","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.3390\/jcm14145135","volume":"14","author":"L Motta","year":"2025","unstructured":"Motta L, Molinari F, Pankovics J, Pedrazzini B, Valera A, Epistolio S, et al. Prognostic impact of KRAS\u2013TP53 co-mutations in patients with early-stage non-small-cell lung cancer: a single-center retrospective study. J Clin Med. 2025;14(14):5135. https:\/\/doi.org\/10.3390\/jcm14145135.","journal-title":"J Clin Med"},{"issue":"17","key":"849_CR115","doi-asserted-by":"publisher","first-page":"e36550","DOI":"10.1016\/j.heliyon.2024.e36550","volume":"10","author":"Z Su","year":"2024","unstructured":"Su Z, El Hage M, Linnebacher M. Mutation patterns in colorectal cancer and their relationship with prognosis. Heliyon. 2024;10(17):e36550.","journal-title":"Heliyon"},{"issue":"8","key":"849_CR116","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1245\/s10434-016-5205-4","volume":"23","author":"OS Chow","year":"2016","unstructured":"Chow OS, Kuk D, Keskin M, Smith JJ, Camacho N, Pelossof R, et al. KRAS and Combined KRAS\/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. Ann Surg Oncol. 2016;23(8):2548\u201355.","journal-title":"Ann Surg Oncol"},{"key":"849_CR117","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cancergen.2022.10.002","volume":"268\u2013269","author":"X Peng","year":"2022","unstructured":"Peng X, Zhang T, Jia X, Wang T, Lin H, Li G, et al. Impact of a haplotype (composed of the APC, KRAS, and TP53 genes) on colorectal adenocarcinoma differentiation and patient prognosis. Cancer Genet. 2022;268\u2013269:115\u201323.","journal-title":"Cancer Genet"},{"issue":"8","key":"849_CR118","doi-asserted-by":"publisher","first-page":"109578","DOI":"10.1016\/j.celrep.2021.109578","volume":"36","author":"D Siolas","year":"2021","unstructured":"Siolas D, Vucic E, Kurz E, Hajdu C, Bar-Sagi D. Gain-of-function p53 R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy. Cell Rep. 2021;36(8):109578.","journal-title":"Cell Rep"},{"issue":"3","key":"849_CR119","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","volume":"17","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, et al. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J Thorac Oncol. 2022;17(3):399\u2013410.","journal-title":"J Thorac Oncol"},{"issue":"24","key":"849_CR120","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1038\/onc.2015.375","volume":"35","author":"MB Schabath","year":"2016","unstructured":"Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, et al. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2016;35(24):3209\u201316.","journal-title":"Oncogene"},{"key":"849_CR121","doi-asserted-by":"publisher","first-page":"806963","DOI":"10.3389\/fonc.2022.806963","volume":"12","author":"DR Principe","year":"2022","unstructured":"Principe DR, Underwood PW, Kumar S, Timbers KE, Koch RM, Trevino JG, et al. Loss of SMAD4 is associated with poor tumor immunogenicity and reduced PD-L1 expression in pancreatic cancer. Front Oncol. 2022;12:806963. https:\/\/doi.org\/10.3389\/fonc.2022.806963.","journal-title":"Front Oncol"},{"issue":"14","key":"849_CR122","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-09-0227","volume":"15","author":"A Blackford","year":"2009","unstructured":"Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009;15(14):4674\u20139.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"849_CR123","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.21037\/tlcr-24-552","volume":"13","author":"M Knetki-Wr\u00f3blewska","year":"2024","unstructured":"Knetki-Wr\u00f3blewska M, Wojas-Krawczyk K, Krawczyk P, Krzakowski M. Emerging insights into STK11, KEAP1 and KRAS mutations: implications for immunotherapy in patients with advanced non-small cell lung cancer. Translational Lung Cancer Res. 2024;13(12):3718\u201330.","journal-title":"Translational Lung Cancer Res"},{"issue":"7","key":"849_CR124","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018;8(7):822\u201335.","journal-title":"Cancer Discov"},{"issue":"7","key":"849_CR125","doi-asserted-by":"publisher","first-page":"e0307580","DOI":"10.1371\/journal.pone.0307580","volume":"19","author":"Y Liang","year":"2024","unstructured":"Liang Y, Maeda O, Kondo C, Nishida K, Ando Y. Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma. PLoS ONE. 2024;19(7):e0307580.","journal-title":"PLoS ONE"},{"issue":"3","key":"849_CR126","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jtho.2022.01.004","volume":"17","author":"R Dziadziuszko","year":"2022","unstructured":"Dziadziuszko R. STK11 and KEAP1 mutations in lung adenocarcinoma: solving the puzzle continues. J Thorac Oncol. 2022;17(3):351\u20132.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"849_CR127","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.ccell.2025.06.011","volume":"43","author":"A Galan-Cobo","year":"2025","unstructured":"Galan-Cobo A, Vokes NI, Qian Y, Molkentine D, Ramkumar K, Paula AG, et al. KEAP1 and STK11\/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS-mutant non-small cell lung cancer. Cancer Cell. 2025;43(8):1530\u2013e489.","journal-title":"Cancer Cell"},{"issue":"1","key":"849_CR128","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-024-01907-z","volume":"9","author":"S Casacuberta-Serra","year":"2024","unstructured":"Casacuberta-Serra S, Gonz\u00e1lez-Larreategui \u00cd, Capit\u00e1n-Leo D, Soucek L. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer. Signal Transduct Target Ther. 2024;9(1):205.","journal-title":"Signal Transduct Target Ther"},{"key":"849_CR129","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/msb.2011.56","volume":"7","author":"D Gaglio","year":"2011","unstructured":"Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol. 2011;7:523.","journal-title":"Mol Syst Biol"},{"issue":"5","key":"849_CR130","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/j.celrep.2014.10.063","volume":"9","author":"BK Wu","year":"2014","unstructured":"Wu BK, Brenner C. Suppression of TET1-dependent DNA demethylation is essential for KRAS-mediated transformation. Cell Rep. 2014;9(5):1827\u201340.","journal-title":"Cell Rep"},{"issue":"1","key":"849_CR131","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/cancers12010229","volume":"12","author":"L Garc\u00eda-Guti\u00e9rrez","year":"2020","unstructured":"Garc\u00eda-Guti\u00e9rrez L, McKenna S, Kolch W, Matallanas D. RASSF1A Tumour Suppressor: Target the Network for Effective Cancer Therapy. Cancers. 2020;12(1):229.","journal-title":"Cancers"},{"key":"849_CR132","doi-asserted-by":"publisher","first-page":"657546","DOI":"10.3389\/fonc.2021.657546","volume":"11","author":"QL Liu","year":"2021","unstructured":"Liu QL, Luo M, Huang C, Chen HN, Zhou ZG. Epigenetic regulation of epithelial-to-mesenchymal transition in the cancer metastatic cascade: implications for cancer therapy. Front Oncol. 2021;11:657546. https:\/\/doi.org\/10.3389\/fonc.2021.657546.","journal-title":"Front Oncol"},{"issue":"1","key":"849_CR133","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1158\/0008-5472.CAN-15-0536","volume":"76","author":"WY Park","year":"2016","unstructured":"Park WY, Hong BJ, Lee J, Choi C, Kim MY. H3K27 Demethylase JMJD3 Employs the NF-\u03baB and BMP Signaling Pathways to Modulate the Tumor Microenvironment and Promote Melanoma Progression and Metastasis. Cancer Res. 2016;76(1):161\u201370.","journal-title":"Cancer Res"},{"key":"849_CR134","doi-asserted-by":"publisher","first-page":"596239","DOI":"10.3389\/fphar.2020.596239","volume":"11","author":"B Dong","year":"2020","unstructured":"Dong B, Qiu Z, Wu Y. Tackle epithelial\u2013mesenchymal transition with epigenetic drugs in cancer. Front Pharmacol. 2020;11:596239. https:\/\/doi.org\/10.3389\/fphar.2020.596239.","journal-title":"Front Pharmacol"},{"issue":"1","key":"849_CR135","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.advms.2022.11.002","volume":"68","author":"S Ardalan Khales","year":"2023","unstructured":"Ardalan Khales S, Forghanifard MM, Abbaszadegan MR, Hosseini SE. EZH2 deregulates BMP, Hedgehog, and Hippo cell signaling pathways in esophageal squamous cell carcinoma. Adv Med Sci. 2023;68(1):21\u201330. https:\/\/doi.org\/10.1016\/j.advms.2022.11.002.","journal-title":"Adv Med Sci"},{"key":"849_CR136","doi-asserted-by":"publisher","first-page":"621093","DOI":"10.3389\/fphar.2020.621093","volume":"11","author":"Y Sun","year":"2020","unstructured":"Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z. Safety and efficacy of bromodomain and extra-terminal inhibitors for hematological malignancies and solid tumors: a systematic study of clinical trials. Front Pharmacol. 2020;11:621093. https:\/\/doi.org\/10.3389\/fphar.2020.621093.","journal-title":"Front Pharmacol"},{"issue":"9","key":"849_CR137","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.3390\/ijms26094364","volume":"26","author":"S Ghafoor","year":"2025","unstructured":"Ghafoor S, Garcia E, Jay DJ, Persad S. Molecular mechanisms regulating epithelial-mesenchymal transition to promote cancer progression. Int J Mol Sci. 2025;26(9):4364.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"849_CR138","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/ncb2976","volume":"16","author":"A Puisieux","year":"2014","unstructured":"Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014;16(6):488\u201394.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"849_CR139","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C. EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2019;29(3):212\u201326.","journal-title":"Trends Cell Biol"},{"issue":"7","key":"849_CR140","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/2211-5463.13415","volume":"12","author":"MK Ichikawa","year":"2022","unstructured":"Ichikawa MK, Endo K, Itoh Y, Osada AH, Kimura Y, Ueki K, et al. Ets family proteins regulate the EMT transcription factors Snail and ZEB in cancer cells. FEBS Open Bio. 2022;12(7):1353\u201364.","journal-title":"FEBS Open Bio"},{"issue":"7","key":"849_CR141","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.7150\/ijbs.108903","volume":"21","author":"A Garc\u00eda de Herreros","year":"2025","unstructured":"Garc\u00eda de Herreros A. Control of Snail1 protein stability by post-translational modifications: the basis for a complex regulation of Snail1 function. Int J Biol Sci. 2025;21(7):3183\u201396.","journal-title":"Int J Biol Sci"},{"key":"849_CR142","doi-asserted-by":"publisher","first-page":"105304","DOI":"10.1016\/j.micpath.2021.105304","volume":"162","author":"AA Hamidi","year":"2022","unstructured":"Hamidi AA, Forghanifard MM, Gholamin M, Moghbeli M, Memar B, Jangjoo A, et al. Elucidated tumorigenic role of MAML1 and TWIST1 in gastric cancer is associated with Helicobacter pylori infection. Microb Pathog. 2022;162:105304. https:\/\/doi.org\/10.1016\/j.micpath.2021.105304.","journal-title":"Microb Pathog"},{"issue":"24","key":"849_CR143","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1038\/onc.2010.115","volume":"29","author":"A Vichalkovski","year":"2010","unstructured":"Vichalkovski A, Gresko E, Hess D, Restuccia DF, Hemmings BA. PKB\/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage. Oncogene. 2010;29(24):3554\u201365.","journal-title":"Oncogene"},{"issue":"7","key":"849_CR144","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.3390\/ijms22073591","volume":"22","author":"E Kang","year":"2021","unstructured":"Kang E, Seo J, Yoon H, Cho S. Post-translational regulation of epithelial\u2013mesenchymal transition-inducing transcription factors in cancer metastasis. Int J Mol Sci. 2021;22(7):3591. https:\/\/doi.org\/10.3390\/ijms22073591.","journal-title":"Int J Mol Sci"},{"key":"849_CR145","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cytogfr.2025.05.004","volume":"85","author":"W Luo","year":"2025","unstructured":"Luo W, Shi Q, Han M, Zhang Z, Reiter RJ, Ashrafizadeh M, et al. TGF-\u03b2-driven EMT in cancer progression and drug resistance. Cytokine Growth Factor Rev. 2025;85:11\u201325.","journal-title":"Cytokine Growth Factor Rev"},{"key":"849_CR146","doi-asserted-by":"publisher","first-page":"1004669","DOI":"10.3389\/fonc.2022.1004669","volume":"12","author":"W Ning","year":"2022","unstructured":"Ning W, Marti TM, Dorn P, Peng RW. Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit. Front Oncol. 2022;12:1004669. https:\/\/doi.org\/10.3389\/fonc.2022.1004669.","journal-title":"Front Oncol"},{"key":"849_CR147","doi-asserted-by":"publisher","first-page":"216859","DOI":"10.1016\/j.canlet.2024.216859","volume":"591","author":"Q Qin","year":"2024","unstructured":"Qin Q, Yu R, Eriksson JE, Tsai H-i, Zhu H. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities. Cancer Lett. 2024;591:216859.","journal-title":"Cancer Lett"},{"key":"849_CR148","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fcell.2020.00152","volume":"8","author":"X Huang","year":"2020","unstructured":"Huang X, Li E, Shen H, Wang X, Tang T, Zhang X, et al. Targeting the HGF\/MET axis in cancer therapy: challenges in resistance and opportunities for improvement. Front Cell Dev Biol. 2020;8:152. https:\/\/doi.org\/10.3389\/fcell.2020.00152.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"849_CR149","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41420-025-02566-x","volume":"11","author":"H Masuda","year":"2025","unstructured":"Masuda H. Cancer-associated fibroblasts in cancer drug resistance and cancer progression: a review. Cell Death Discov. 2025;11(1):341.","journal-title":"Cell Death Discov"},{"issue":"34","key":"849_CR150","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741\u201351.","journal-title":"Oncogene"},{"issue":"7","key":"849_CR151","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00204-021-03063-7","volume":"95","author":"J De Las Rivas","year":"2021","unstructured":"De Las Rivas J, Brozovic A, Izraely S, Casas-Pais A, Witz IP, Figueroa A. Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch Toxicol. 2021;95(7):2279\u201397.","journal-title":"Arch Toxicol"},{"issue":"14","key":"849_CR152","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1158\/0008-5472.CAN-17-0392","volume":"77","author":"J Antony","year":"2017","unstructured":"Antony J, Huang RY-J. AXL-Driven EMT State as a Targetable Conduit in Cancer. Cancer Res. 2017;77(14):3725\u201332.","journal-title":"Cancer Res"},{"issue":"6","key":"849_CR153","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s11010-021-04089-2","volume":"476","author":"RA Mahmoudian","year":"2021","unstructured":"Mahmoudian RA, Gharaie ML, Abbaszadegan MR, Alasti A, Forghanifard MM, Mansouri A, et al. Crosstalk between MMP-13, CD44, and TWIST1 and its role in regulation of EMT in patients with esophageal squamous cell carcinoma. Mol Cell Biochem. 2021;476(6):2465\u201378. https:\/\/doi.org\/10.1007\/s11010-021-04089-2.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"849_CR154","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-024-01631-9","volume":"17","author":"X Yang","year":"2024","unstructured":"Yang X, Wu H. RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms. J Hematol Oncol. 2024;17(1):108.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"849_CR155","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1158\/0008-5472.CAN-18-2711","volume":"79","author":"TK Hayes","year":"2019","unstructured":"Hayes TK, Luo F, Cohen O, Goodale AB, Lee Y, Pantel S, et al. A Functional Landscape of Resistance to MEK1\/2 and CDK4\/6 Inhibition in NRAS-Mutant Melanoma. Cancer Res. 2019;79(9):2352\u201366.","journal-title":"Cancer Res"},{"key":"849_CR156","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.biochi.2019.08.003","volume":"165","author":"M Karimi Roshan","year":"2019","unstructured":"Karimi Roshan M, Soltani A, Soleimani A, Rezaie Kahkhaie K, Afshari AR, Soukhtanloo M. Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process. Biochimie. 2019;165:229\u201334.","journal-title":"Biochimie"},{"issue":"7443","key":"849_CR157","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature12040","volume":"496","author":"J Son","year":"2013","unstructured":"Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101\u20135.","journal-title":"Nature"},{"issue":"3","key":"849_CR158","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying H, Kimmelman Alec C, Lyssiotis Costas A, Hua S, Chu Gerald C, Fletcher-Sananikone E, et al. Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism. Cell. 2012;149(3):656\u201370.","journal-title":"Cell"},{"issue":"7451","key":"849_CR159","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nature12138","volume":"497","author":"C Commisso","year":"2013","unstructured":"Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013;497(7451):633\u20137. https:\/\/doi.org\/10.1038\/nature12138.","journal-title":"Nature"},{"issue":"6","key":"849_CR160","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.cmet.2022.04.003","volume":"34","author":"SA Best","year":"2022","unstructured":"Best SA, Gubser PM, Sethumadhavan S, Kersbergen A, Negr\u00f3n Abril YL, Goldford J, et al. Glutaminase inhibition impairs CD8 T cell activation in STK11-\/Lkb1-deficient lung cancer. Cell Metabol. 2022;34(6):874\u2013e876.","journal-title":"Cell Metabol"},{"issue":"18","key":"849_CR161","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-21-1204","volume":"27","author":"JJ Harding","year":"2021","unstructured":"Harding JJ, Telli M, Munster P, Voss MH, Infante JR, DeMichele A, et al. A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2021;27(18):4994\u20135003.","journal-title":"Clin Cancer Res"},{"key":"849_CR162","doi-asserted-by":"publisher","first-page":"1185093","DOI":"10.3389\/fonc.2023.1185093","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang Z, He R, Dong S, Zhou W. Pancreatic stellate cells in pancreatic cancer: potential targets for future therapy. Front Oncol. 2023;13:1185093. https:\/\/doi.org\/10.3389\/fonc.2023.1185093.","journal-title":"Front Oncol"},{"issue":"770","key":"849_CR163","doi-asserted-by":"publisher","first-page":"eado2402","DOI":"10.1126\/scitranslmed.ado2402","volume":"16","author":"X Liu","year":"2024","unstructured":"Liu X, Baer JM, Stone ML, Knolhoff BL, Hogg GD, Turner MC, et al. Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. Sci Transl Med. 2024;16(770):eado2402.","journal-title":"Sci Transl Med"},{"key":"849_CR164","doi-asserted-by":"publisher","first-page":"576399","DOI":"10.3389\/fonc.2020.576399","volume":"10","author":"B Jiang","year":"2020","unstructured":"Jiang B, Zhou L, Lu J, Wang Y, Liu C, You L, et al. Stroma-targeting therapy in pancreatic cancer: one coin with two sides? Front Oncol. 2020;10:576399. https:\/\/doi.org\/10.3389\/fonc.2020.576399.","journal-title":"Front Oncol"},{"issue":"27","key":"849_CR165","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.20.00590","volume":"38","author":"EV Cutsem","year":"2020","unstructured":"Cutsem EV, Tempero MA, Sigal D, Oh D-Y, Fazio N, Macarulla T, et al. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020;38(27):3185\u201394.","journal-title":"J Clin Oncol"},{"issue":"5","key":"849_CR166","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/cancers17050785","volume":"17","author":"P Uniyal","year":"2025","unstructured":"Uniyal P, Kashyap VK, Behl T, Parashar D, Rawat R. KRAS mutations in cancer: understanding signaling pathways to immune regulation and the potential of immunotherapy. Cancers (Basel). 2025;17(5):785.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"849_CR167","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12964-023-01063-x","volume":"21","author":"A Watterson","year":"2023","unstructured":"Watterson A, Coelho MA. Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions. Cell Communication Signal. 2023;21(1):45.","journal-title":"Cell Communication Signal"},{"issue":"29","key":"849_CR168","doi-asserted-by":"publisher","first-page":"eabm8780","DOI":"10.1126\/sciadv.abm8780","volume":"8","author":"E Mugarza","year":"2022","unstructured":"Mugarza E, van Maldegem F, Boumelha J, Moore C, Rana S, Llorian Sopena M, et al. Therapeutic KRAS(G12C) inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci Adv. 2022;8(29):eabm8780.","journal-title":"Sci Adv"},{"issue":"5","key":"849_CR169","doi-asserted-by":"publisher","first-page":"e013671","DOI":"10.1136\/jitc-2025-013671","volume":"14","author":"MZ Tesfay","year":"2026","unstructured":"Tesfay MZ, Cios A, Cheng Z, Ferdous KU, Shelton RS, Mustafa B, et al. Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response. J Immunother Cancer. 2026;14(5):e013671. https:\/\/doi.org\/10.1136\/jitc-2025-013671.","journal-title":"J Immunother Cancer"},{"key":"849_CR170","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2023.04.008","volume":"188","author":"A Zaremba","year":"2023","unstructured":"Zaremba A, Mohr P, Gutzmer R, Meier F, Pf\u00f6hler C, Weichenthal M, et al. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG. Eur J Cancer. 2023;188:140\u201351.","journal-title":"Eur J Cancer"},{"key":"849_CR171","doi-asserted-by":"publisher","first-page":"691032","DOI":"10.3389\/fimmu.2021.691032","volume":"12","author":"L Zhou","year":"2021","unstructured":"Zhou L, Wang X, Chi Z, Sheng X, Kong Y, Mao L, et al. Association of NRAS mutation with clinical outcomes of anti-PD-1 monotherapy in advanced melanoma: a pooled analysis of four Asian clinical trials. Front Immunol. 2021;12:691032. https:\/\/doi.org\/10.3389\/fimmu.2021.691032.","journal-title":"Front Immunol"},{"issue":"7","key":"849_CR172","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3390\/jcm13072103","volume":"13","author":"F Nusrat","year":"2024","unstructured":"Nusrat F, Khanna A, Jain A, Jiang W, Lavu H, Yeo CJ, et al. The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma. J Clin Med. 2024;13(7):2103.","journal-title":"J Clin Med"},{"issue":"22","key":"849_CR173","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","volume":"184","author":"BT Gr\u00fcnwald","year":"2021","unstructured":"Gr\u00fcnwald BT, Devisme A, Andrieux G, Vyas F, Aliar K, McCloskey CW, et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell. 2021;184(22):5577\u2013e9218.","journal-title":"Cell"},{"issue":"11","key":"849_CR174","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly J, Hoffman MT, Abbassi L, Li Z, Paradiso F, Parent BD, et al. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discov. 2024;14(11):2135\u201361.","journal-title":"Cancer Discov"},{"issue":"1","key":"849_CR175","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10\u201332.","journal-title":"Ann Oncol"},{"key":"849_CR176","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer. 21 Jun 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer. Accessed 22 Jul 2026."},{"key":"849_CR177","unstructured":"US Food and Drug Administration. Withdrawn | Cancer Accelerated Approvals. Krazati (adagrasib) in combination with cetuximab for KRAS G12C-mutated locally advanced or metastatic colorectal cancer; withdrawal date 1 Sep 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/withdrawn-cancer-accelerated-approvals. Accessed 4 Oct 2026."},{"key":"849_CR178","unstructured":"US Food and Drug Administration. FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer. 16. Jan 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-sotorasib-panitumumab-kras-g12c-mutated-colorectal-cancer. Accessed 22 Jul 2026."},{"key":"849_CR179","unstructured":"US Food and Drug Administration. Use of circulating tumor DNA for early-stage solid tumor drug development: guidance for industry. 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development. Accessed 22 Jul 2026."},{"issue":"4 Suppl","key":"849_CR180","first-page":"TPS326","volume":"43","author":"TW Kim","year":"2025","unstructured":"Kim TW, Price T, Grasselli J, Strickler JH, Masuishi T, Kwok GW, et al. CodeBreaK 301: a phase 3 study of first-line sotorasib, panitumumab and FOLFIRI in KRAS G12C-mutated metastatic colorectal cancer [trial-design abstract]. J Clin Oncol. 2025;43(4 Suppl):TPS326.","journal-title":"J Clin Oncol"},{"key":"849_CR181","doi-asserted-by":"publisher","first-page":"107254","DOI":"10.1016\/j.lungcan.2023.107254","volume":"181","author":"FT Gallina","year":"2023","unstructured":"Gallina FT, Marinelli D, Melis E, Forcella D, Taje R, Buglioni S, et al. KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma. Lung Cancer. 2023;181:107254.","journal-title":"Lung Cancer"},{"key":"849_CR182","unstructured":"US Food and Drug Administration. LUMAKRAS (sotorasib) prescribing information. Revised. Jan 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/214665s009lbl.pdf. Accessed 22 Jul 2026."},{"issue":"10378","key":"849_CR183","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ de Langen","year":"2023","unstructured":"de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023;401(10378):733\u201346.","journal-title":"Lancet"},{"key":"849_CR184","first-page":"100743","volume":"36","author":"A Desai","year":"2023","unstructured":"Desai A, Rakshit S, Bansal R, Ashara Y, Potter A, Manochakian R, et al. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report. Cancer Treat Res Commun. 2023;36:100743.","journal-title":"Cancer Treat Res Commun"},{"key":"849_CR185","doi-asserted-by":"publisher","first-page":"105074","DOI":"10.1016\/j.ebiom.2024.105074","volume":"102","author":"SM Ernst","year":"2024","unstructured":"Ernst SM, van der Hofman MM, Paats MS, Heijboer FWJ, Aerts J, et al. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis. EBioMedicine. 2024;102:105074.","journal-title":"EBioMedicine"},{"key":"849_CR186","doi-asserted-by":"publisher","first-page":"e2300030","DOI":"10.1200\/PO.23.00030","volume":"7","author":"R Thummalapalli","year":"2023","unstructured":"Thummalapalli R, Bernstein E, Herzberg B, Li BT, Iqbal A, Preeshagul I, et al. Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer. JCO Precis Oncol. 2023;7:e2300030.","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"849_CR187","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(25)00298-X","volume":"14","author":"J Luo","year":"2026","unstructured":"Luo J, Villaruz LC. Combined SHP2 and KRAS G12C inhibitor therapy in patients with non-small-cell lung cancer. Lancet Respir Med. 2026;14(2):107\u20139.","journal-title":"Lancet Respir Med"},{"key":"849_CR188","doi-asserted-by":"publisher","first-page":"1380584","DOI":"10.3389\/fonc.2024.1380584","volume":"14","author":"H Miyashita","year":"2024","unstructured":"Miyashita H, Kato S, Hong DS. KRAS G12C inhibitor combination therapies: current evidence and challenges. Front Oncol. 2024;14:1380584. https:\/\/doi.org\/10.3389\/fonc.2024.1380584.","journal-title":"Front Oncol"},{"issue":"4","key":"849_CR189","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang X, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A, et al. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS(G12D) Inhibitor. J Med Chem. 2022;65(4):3123\u201333.","journal-title":"J Med Chem"},{"issue":"9","key":"849_CR190","doi-asserted-by":"publisher","first-page":"22976","DOI":"10.3390\/ijms160922976","volume":"16","author":"S Temraz","year":"2015","unstructured":"Temraz S, Mukherji D, Shamseddine A. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. Int J Mol Sci. 2015;16(9):22976\u201388.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"849_CR191","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/1078-0432.CCR-14-1814","volume":"21","author":"PL Bedard","year":"2015","unstructured":"Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, et al. A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1\/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors. Clin Cancer Res. 2015;21(4):730\u20138.","journal-title":"Clin Cancer Res"},{"issue":"Suppl10","key":"849_CR192","doi-asserted-by":"publisher","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","volume":"30","author":"SE Nunnery","year":"2019","unstructured":"Nunnery SE, Mayer IA. Management of toxicity to isoform \u03b1-specific PI3K inhibitors. Ann Oncol. 2019;30(Suppl10):x21\u20136.","journal-title":"Ann Oncol"},{"issue":"5","key":"849_CR193","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12032-025-02667-8","volume":"42","author":"C Himani, Kaur","year":"2025","unstructured":"Himani, Kaur C, Kumar R, Mishra R, Singh G. Targeting TGF-\u03b2: a promising strategy for cancer therapy. Med Oncol. 2025;42(5):142.","journal-title":"Med Oncol"},{"issue":"1","key":"849_CR194","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/s41467-017-01968-5","volume":"8","author":"J Zhang","year":"2017","unstructured":"Zhang J, Cunningham JJ, Brown JS, Gatenby RA. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat Commun. 2017;8(1):1816.","journal-title":"Nat Commun"},{"issue":"9 Suppl","key":"849_CR195","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jtho.2022.07.025","volume":"17","author":"BT Li","year":"2022","unstructured":"Li BT, Falchook GS, Durm GA, Burns TF, Skoulidis F, Ramalingam SS, et al. CodeBreaK 100\/101: safety and efficacy of sotorasib combined with pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC [conference abstract]. J Thorac Oncol. 2022;17(9 Suppl):S10\u20131.","journal-title":"J Thorac Oncol"},{"issue":"16 Suppl","key":"849_CR196","doi-asserted-by":"publisher","first-page":"8500","DOI":"10.1200\/JCO.2025.43.16_suppl.8500","volume":"43","author":"PA Janne","year":"2025","unstructured":"Janne PA, Theelen WSME, Garassino MC, Spira AI, Laskin JJ, De Marinis F, et al. First-line adagrasib with pembrolizumab in advanced or metastatic KRAS G12C-mutated non-small-cell lung cancer: phase 2 KRYSTAL-7 results [conference abstract]. J Clin Oncol. 2025;43(16 Suppl):8500.","journal-title":"J Clin Oncol"},{"key":"849_CR197","unstructured":"ClinicalTrials.gov. Neoadjuvant sotorasib with platinum and pemetrexed for resectable KRAS G12C-mutant non-squamous non-small-cell lung cancer (NCT05118854). https:\/\/clinicaltrials.gov\/study\/NCT05118854. Accessed 22 Jul 2026."},{"issue":"1","key":"849_CR198","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","volume":"30","author":"JS Deutsch","year":"2024","unstructured":"Deutsch JS, Cimino-Mathews A, Thompson E, Provencio M, Forde PM, Spicer J, et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat Med. 2024;30(1):218\u201328.","journal-title":"Nat Med"},{"issue":"5","key":"849_CR199","first-page":"100670","volume":"5","author":"KI Zhou","year":"2024","unstructured":"Zhou KI, Lin C, Tseng CL, Ramnath N, Dowell JE, Kelley MJ. Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C-Mutated NSCLC. JTO Clin Res Rep. 2024;5(5):100670.","journal-title":"JTO Clin Res Rep"},{"key":"849_CR200","doi-asserted-by":"publisher","first-page":"115301","DOI":"10.1016\/j.ejca.2025.115301","volume":"219","author":"M Wislez","year":"2025","unstructured":"Wislez M, Mascaux C, Cadranel J, Thomas QD, Ricordel C, Swalduz A, et al. Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study. Eur J Cancer. 2025;219:115301.","journal-title":"Eur J Cancer"},{"issue":"6","key":"849_CR201","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.molonc.2014.06.005","volume":"8","author":"RA Burrell","year":"2014","unstructured":"Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. 2014;8(6):1095\u2013111.","journal-title":"Mol Oncol"},{"issue":"5","key":"849_CR202","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1158\/1078-0432.CCR-24-2948","volume":"31","author":"K Jazieh","year":"2025","unstructured":"Jazieh K, Tsai J, Solomon S, Zhu M, Sinicrope FA, Pedersen KS, et al. Identification of Candidate Alterations Mediating KRASG12C Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers. Clin Cancer Res. 2025;31(5):899\u2013906.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"849_CR203","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","volume":"16","author":"T Koga","year":"2021","unstructured":"Koga T, Suda K, Fujino T, Ohara S, Hamada A, Nishino M, et al. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. J Thorac Oncol. 2021;16(8):1321\u201332.","journal-title":"J Thorac Oncol"},{"issue":"16","key":"849_CR204","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1158\/1078-0432.CCR-17-3674","volume":"24","author":"BS Jaiswal","year":"2018","unstructured":"Jaiswal BS, Durinck S, Stawiski EW, Yin J, Wang W, Lin E, et al. ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy. Clin Cancer Res. 2018;24(16):4044\u201355.","journal-title":"Clin Cancer Res"},{"key":"849_CR205","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ctrv.2018.12.003","volume":"73","author":"P Janiaud","year":"2019","unstructured":"Janiaud P, Serghiou S, Ioannidis JPA. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treat Rev. 2019;73:20\u201330.","journal-title":"Cancer Treat Rev"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00849-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00849-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00849-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:03:42Z","timestamp":1793966622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00849-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":205,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00849-2","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"2 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This article is a narrative review based on previously published studies and publicly available information and does not involve the recruitment of human participants, the collection of human specimens, or experiments involving animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"108"}}